A Phase 2 interventional study of Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate in Inflammatory Bowel Diseases, sponsored by Polyclinique de l'Europe. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Polyclinique de l'Europe · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Inflammatory Bowel Diseases with a site in France — 31 open to participants now, 42 under way, 7 of them phase 3. Inflammatory Bowel Diseases · France.
Among the 143 studies in Inflammatory Bowel Diseases with a site in France, this one is the 71st largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2024, is one of 19 in phase 2, reaches primary completion later than 16 of the 41 other live ones, and was the 121st registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →31 of the 143 studies in Inflammatory Bowel Diseases with a site in France are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in France
Ages 18+
Palisade Bio · Sites in France, United States, Canada and 9 more countries
Ages 18–75
Raincy Montfermeil Hospital Group · Sites in France
Ages 18+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
Spyre Therapeutics, Inc. · Sites in France, United States, Argentina and 33 more countries
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 27 · Phase 4 2
First in 1990; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 124 across the 84 interventional studies, 220 across the 59 observational. Of the 95 that completed or were terminated, 25 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 143 have an industry lead sponsor. The 10 most frequent:
Polyclinique de l'Europe is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Polyclinique de l'Europe has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Inflammatory Bowel Diseases with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04997733Phase 3Assistance Publique - Hôpitaux de ParisFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal | 2027-05-22 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT06261320Polyclinique de l'EuropeMesotherapy Treatment of Irritable Bowel Syndrome | 2026-12-31 |
| NCT06805890Assistance Publique Hopitaux De MarseilleStudy of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology | 2027-03-24 |
| NCT05251415University Hospital, ToulouseClinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases | 2027-04-04 |
Add all 10 to your calendar (.ics) → With an account.
Among the 143 studies in Inflammatory Bowel Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.
Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.
Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
Irritable Bowel Syndrome Symptom Severity Scale(IBS-SSS)
Includes 5 items regarding pain (intensity and number of days), abdominal distention, satisfaction of bowel habit, and interference of daily life of the last 10 d on a 10-point scale. Gives a score between 0 and 500, and groups of severity can be made: mild (≤175), moderate (175-300), and severe (≥300) IBS.
Time frame: day 8, day 15, day 30, day 45
Functional Digestive Disorders Quality of Life questionnaire (FDDQL)
43 items with 8 subscales : daily activity, anxiety, nutrition, sleep, discomfort, health perception, adaptation and impact of stress Global score is between 0 and 100.
Time frame: day 30, day 45
Pain evaluation
Evaluation of pain with a scale from 0 (no pain) to 10 (worst pain imagined)
Time frame: day 8, day 15, day 30, day 45
Global satisfaction
4 questions with Likert scale of 5 items, to "not at all satisfied" to "very satisfied"
Time frame: day 45
Anxiety evaluation : Questionnaire "Hospital anxiety and depression scale"
14 items with 7 about depression and 7 about anxiety. Each item is noted with a Likert scale of 4 points, from 0 (no symptoms) to 3 (strong symptoms).
Time frame: day 30, day 45
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.
Of 34 non-industry phase 2 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's planned 34 months is above that.
Counting every sponsor, half of 61 studies reached it within 27 months; a quarter within 18 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyclinique de l'Europe